Targeting interferon regulatory factors to inhibit activation of the type I IFN response: Implications for treatment of autoimmune disorders

Cellular Immunology

Volumn 271, Issue 2, 2011, Pages 342-349

  Sweeney, Susan E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Autoimmune disease; Interferon regulatory factors; Monocytes; Transcription factors; Type I interferon

Indexed keywords

BETA INTERFERON; CHEMOKINE; CPG 10101; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL CULTURE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTERFERON INDUCTION; MONOCYTE MACROPHAGE PRECURSOR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPORTER GENE; RNA STABILITY;

AUTOIMMUNE DISEASES; CELL LINE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; INTERFERON REGULATORY FACTORS; INTERFERON TYPE I; INTERLEUKIN-6; MONOCYTES; PROMOTER REGIONS, GENETIC; RNA STABILITY; RNA, SMALL INTERFERING;

EID: 80054048063     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.07.014     Document Type: Article

References (35)

1. Vallin H., Perers A., Alm G., Ronnblom L. Anti-double stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J. Immunol. 1999, 163:6306-6313.
2. Bennett L., Palucka A., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
3. Crow M. Interferon pathway activation in systemic lupus erythematosus. Curr. Rheumatol. Rep. 2005, 7:463-468.
4. Baechler E., Gregersen P., Behrens T. The emerging role of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 2004, 16:801-807.
5. Baechler E., Batliwalla F., Karypis G., Gaffney P., Ortmann W., Espe K., Shark K., Grande W., Hughes K., Kapur V., Gregersen P., Behrens T. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003, 100:2610-2615.
6. Crow M.K., Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 2003, 5:279-287.
7. Brentano F., Kyburz D., Schorr O., Gay R., Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell. Immunol. 2005, 233:90-96.
8. Sweeney S., Mo L., Firestein G. Antiviral gene expression in rheumatoid arthritis: role of IKK epsilon and interferon regulatory factor 3. Arthritis Rheum. 2007, 56:743-752.
9. Sweeney S., Kimbler T., Firestein G. Synoviocyte innate immune responses II pivotal role of IFN regulatory factor 3. J. Immunol. 2010, 15:7162-7168.
10. Yoshizawa T., Hammaker D., Sweeney S., Boyle D., Firestein G. Synoviocyte innate immune responses: I. Differential regulation of interferon responses and the JNK pathway by MAPK kinases. J. Immunol. 2008, 181:3252-3258.
11. Sweeney S.E., Firestein G.S. Signal transduction in rheumatoid arthritis. Curr. Opin. Rheumatol. 2004, 16:231-237.
12. Firestein G. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 2005, 11:S39-S44.
13. van Holten J., Smeets T.J., Blankert P., Tak P.P. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann. Rheum. Dis. 2005, 64:1780-1782.
14. Haringman J.J., Smeets T.J., Reinders-Blankert P., Tak P.P. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. 2006, 65:294-300.
15. Garcia-Vicuna R., Gomez-Gaviro M.V., Dominguez-Luis M.J., Pec M.K., Gonzalez-Alvaro I., Alvaro-Gracia J.M., Diaz-Gonzalez F. CC and CXC chemokine receptors mediate migration, Proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 2004, 50:3866-3877.
16. Koch A.E., Kunkel S.L., Harlow L.A., Johnson B., Evanoff H.L., Haines G.K., Burdick M.D., Pope R.M., Strieter R.M. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest. 1992, 90:772-779.
17. Olsen N., Sokka T., Seehorn C., Kraft B., Maas K., Moore J., Aune T. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann. Rheum. Dis. 2004, 63:1387-1392.
18. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell. Immunol. 2006, 124:783-801.
19. Chi H., Flavell R. Innate recognition of non-self nucleic acids. Genome Biol. 2008, 9:211.
20. Diebold S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
21. Means T., Latz E., Hayashi F., Murali M., Golenbock D., Luster A. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 2005, 115:407-417.
22. Ardoin S., Pisetsky D. Developments in the scientific understanding of lupus. Arthritis Res. Ther. 2008, 10:218.
23. Kim T.K., Kim T.H., Maniatis T. Efficient recruitment of TFIIB and CBP-RNA polymerase II holoenzyme by an interferon-enhanceosome in vitro. Proc. Natl. Acad. Sci. USA 1998, 95:12191-12196.
24. Honda K., Taniguchi T., Fs I.R. Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6:644-658.
25. Romieu-Mourez R., Solis M., Nardin A., Goubau D., Baron-Bodo V., Lin R., Massie B., Salcedo M., Hiscott J. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res. 2006, 66:10576-10585.
26. Génin P., Lin R., Hiscott J., Civas A. Differential regulation of human interferon a gene expression by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 2009, 29:3435-3450.
27. Goubau D., Romieu-Mourez R., Solis M., Hernandez E., Mesplède T., Lin R., Leaman D., Hiscott J. Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7. Eur. J. Immunol. 2009, 39:527-540.
28. Sweeney S.E., Hammaker D., Boyle D.L., Firestein G.S. Regulation of c-Jun phosphorylation by the I kappa B kinase-epsilon complex in fibroblast-like synoviocytes. J. Immunol. 2005, 174:6424-6430.
29. Boyle D.L., Rosengren S., Bugbee W., Kavanaugh A., Firestein G.S. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res. Ther. 2003, 5:R352-R360.
30. Paschoud S., Dogar A., Kuntz C., Grisoni-Neupert B., R L., Kuhn L. Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-binding protein AUF1. Mol. Cell. Biol. 2006, 26:8228-8241.
31. Niewold T., Kelly J., Flesch M., Espinoza L., Harley J., Crow M. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2481-2487.
32. Salloum R., Franek B., Kariuki S., Rhee L., Mikolaitis R., Jolly M., Utset T., Niewold T.B. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010, 62:553-561.
33. Sweeney S.E. Hematopoietic stem cell transplant for systemic lupus erythematosus: Interferon regulatory factor 7 activation correlates with the IFN signature and recurrent disease. Lupus 2010.
34. Takaoka A., Yanai H., Kondo S., Duncan G., Negishi H., Mizutani T., Kano S., Honda K., Ohba Y., Mak T., Taniguchi T. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005, 434:243-249.
35. Savitsky D., Tamura T., Yanai H., Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol. Immunother. 2010, 59:489-510.